Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.59 |
| ▸ | GHSR | Q92847 | 1/20 | 0.55 |
| ▸ | ECE1 | P42892 | 4/20 | 0.55 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.54 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.54 |
| ▸ | ITGAL | P20701 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31593293 | 0.94 | ACE (0.53) | ACEGHSRECE1LTA4H | |
| SCHEMBL31593374 | 0.93 | GHSR (0.64) | ACEGHSR | |
| SCHEMBL30051742 | 0.92 | ACE (0.68) | ACEECE1ERAP2LTA4HP2RY14 | |
| SCHEMBL31593292 | 0.90 | GHSR (0.57) | ACEGHSR | |
| SCHEMBL29867952 | 0.90 | GHSR (0.62) | ACEGHSRECE1ERAP2LTA4H | |
| SCHEMBL30051248 | 0.88 | LTA4H (0.67) | ACEGHSRECE1LTA4H | |
| SCHEMBL30052824 | 0.88 | LTA4H (0.67) | ACEGHSRECE1LTA4H | |
| SCHEMBL30051633 | 0.88 | ACE (0.58) | ACEGHSRECE1P2RY14ALOX15 | |
| SCHEMBL1407979 | 0.88 | ALOX15 (0.68) | ACEERAP2P2RY14ALOX15ITGB2 | |
| SCHEMBL1407978 | 0.88 | ALOX15 (0.68) | ACEERAP2P2RY14ALOX15ITGB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | ACE 2907/4885GHSR 2961/4885ECE1 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.